• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BSGM

    BioSig Technologies Inc.

    Subscribe to $BSGM
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

    IPO Year:

    Exchange: NASDAQ

    Website: biosig.com

    Recent Analyst Ratings for BioSig Technologies Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    BioSig Technologies Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

      Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq. Proposed Transaction Highlights include: Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.  Commodity-focused real-world asset

      5/5/25 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

      Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that its common stock will continue trading on The Nasdaq Capital Market ("Nasdaq"). On March 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC confirming that it has met the required minimum stockholders' equity threshold of $2.5M as outlined in Listing Rule 5550(b). As a result, the Company's previously disclosed deficiency has been resolved, and the Company now remains in full compliance with all applicable Na

      3/26/25 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement

      Los Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization,  today announced that it has received notice from the Nasdaq Listing Qualifications staff ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). To regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days; on November 13, 2024, Nasdaq informed

      11/13/24 3:14:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

      Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities ("MVLS") requirement previously became non-compliant. BioSig's CEO, Anthony Amato stated, "We'd li

      10/22/24 3:13:31 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation

      Los Angeles, July 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization for electrophysiology (EP) procedures, today announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools. A non-binding letter of intent (LOI) has been executed confirming BioSig's preliminary interest in the proposed acquisition of the assets of NKC. The purchase price will be paid through the issuance of shares of BioSig's common stock to the shareholders o

      7/31/24 9:45:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

      Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that it has successfully negotiated with multiple vendors an initial reduction in accounts payable of approximately $1.5 million during the second quarter of 2024 since new management has taken leadership. One substantial savings recognized is for the successful termination of the office lease expense for the former headquarters in Westport, Connecticut as of July 15, 2024 which was set to end on December 31, 2024.

      7/25/24 1:57:13 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

      Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director

      6/10/24 9:45:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

      Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company") a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants are immediately exercisable and will expire five years from the

      5/30/24 4:05:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

      Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company") a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, BioSig has also agreed to issue and sell to the same purchasers unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1

      5/30/24 8:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

      Westport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, has today issued the following Letter to Shareholders: Dear Shareholders, As the new CEO of BioSig, I am committed to keeping our shareholders updated to the best of my ability on the progress of our Company. Our new management team is firmly committed to both restoring and creating lasting shareholder value and we believe our recent progress is the beginning of a successful foundation for growth. Over the past two months, BioSig has realized important and

      5/21/24 11:10:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioSig Technologies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CFO Groenewald Ferdinand was granted 35,000 shares, increasing direct ownership by 140% to 60,000 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:56 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Amato Anthony N. was granted 23,345 shares, increasing direct ownership by 1% to 2,131,547 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:54 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Abelman Steven Eric was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:47 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Baer Christopher Allen was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:49 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Browne Donald was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:50 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Hrkac Frederick was granted 23,345 shares, increasing direct ownership by 4% to 612,846 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:51 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Groenewald Ferdinand claimed ownership of 25,000 shares (SEC Form 3)

      3 - BioSig Technologies, Inc. (0001530766) (Issuer)

      1/15/25 4:58:47 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Amato Anthony N. was granted 1,550,000 shares, increasing direct ownership by 278% to 2,108,202 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      9/13/24 4:05:21 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Abelman Steven Eric was granted 30,000 shares, increasing direct ownership by 60% to 80,000 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      7/30/24 9:27:48 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Baer Christopher Allen was granted 30,000 shares, increasing direct ownership by 60% to 80,000 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      7/30/24 9:25:55 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioSig Technologies Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on BioSig Technologies with a new price target

      The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

      2/8/21 7:32:50 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioSig Technologies Inc. SEC Filings

    See more
    • BioSig Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/5/25 9:17:41 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 8-K filed by BioSig Technologies Inc.

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      4/30/25 3:37:34 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      4/28/25 7:51:54 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      4/15/25 5:00:10 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-K filed by BioSig Technologies Inc.

      10-K - BioSig Technologies, Inc. (0001530766) (Filer)

      4/15/25 4:29:15 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-K filed by BioSig Technologies Inc.

      NT 10-K - BioSig Technologies, Inc. (0001530766) (Filer)

      3/31/25 4:14:26 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form D filed by BioSig Technologies Inc.

      D - BioSig Technologies, Inc. (0001530766) (Filer)

      3/26/25 5:00:12 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Other Events

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      3/25/25 9:00:25 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Other Events

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      3/6/25 2:43:59 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      3/5/25 3:54:52 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioSig Technologies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      11/14/24 3:58:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioSig Technologies Inc.

      SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      2/14/24 3:31:45 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      7/12/21 8:29:21 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed

      SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      2/2/21 3:13:40 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioSig Technologies Inc. Financials

    Live finance-specific insights

    See more
    • BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

      Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

      9/22/22 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig to Host Conference Call on December 21, 2021

      Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

      12/13/21 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioSig Technologies Inc. Leadership Updates

    Live Leadership Updates

    See more
    • BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

      Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq. Proposed Transaction Highlights include: Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.  Commodity-focused real-world asset

      5/5/25 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

      Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director

      6/10/24 9:45:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

      Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer ("CEO"), effective immediately.  Additionally, Mr. Amato will serve on the Company's Board of Directors, which is currently being assembled.  Recall, that on April 4, 2024, the Company announced the engagement of Consulting firm, Bridge Associates International Pharmaceutical Consulting ("BAIPC"), led by Mr. Amato.  This corporate action was the natural progressi

      4/30/24 2:03:14 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP

      Westport, CT, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Westport, CT, November 7, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced the appointment of Frederick Hrkac to the new role of Executive Vice President, effective as of November 2, 2023. Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe. Since April 2022, he has served on the BioSig Board of Directors and as Chairman of the nominating and corporate governance committee. As a result of his appoi

      11/7/23 8:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Announces New Advisory Board Member Edwin Wang

      Westport, CT, March 27, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of new Advisory Board member Edwin Wang. Mr. Wang has over 20 years of impactful experience in private equity, venture capital, merchant banking, and family office investing. He is the founder of Accretive Capital Partners LLC, a pioneering direct investment sponsor in middle market private equity that raised, invested and harvested a top quartile secondary dire

      3/27/23 8:38:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Announces New Advisory Board Member Lorraine Spurge

      Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory Board. As founder and CEO of Maple Stone Capital Advisors, Ms. Spurge began her 40-year financial career with Drexel Burnham Lambert and became one of the most successful women on Wall Street. She helped raise more than $200 billion of debt and equity capital for growth companies. The capital she hel

      3/24/23 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy

      Westport, CT, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly joins BioSig as CFOBuhaly brings 15 years of public company CFO experience, including 9 years of leadership with RF chip technology giant Qorvo BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the retirement of chief financial officer Steve Chaussy following a distinguished career with the Company, and has named Steve Buhaly as his successor. Mr. Buhaly b

      2/7/23 8:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth

      Westport, CT, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Company increases sales efforts and strategy, adds new National Account Executives to accelerate commercial growth Strengthens marketing team with new marketing and communications programs highlighting competitive market advantage BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it has expanded its marketing and sales teams to scale and support the national commercial rollout of its PURE EP™ System. BioSig recently doubled the s

      8/30/22 9:37:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Sees Positive Momentum from Sales Pipeline Growth

      Westport, CT, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Company sees increase in medical centers entering into 60-day evaluation agreements Existing customers seeing positive results from PURE EP™ System expected to increase number of units purchased BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it is seeing positive momentum from the growth of its sales pipeline, and expects to see an increase in enterprise adoption of its PURE EP™ System  in the coming months. Since BioSig's national

      8/16/22 9:47:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer

      Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer. Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories (NYSE:ABT). During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice P

      3/16/22 9:00:00 AM ET
      $ABT
      $BSGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus